211 related articles for article (PubMed ID: 31996792)
21. Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia.
Salas MQ; Chen S; Lam W; Pasic I; Gerbitz A; Michelis FV; Kim DDH; Al-Shaibani Z; Lipton JH; Mattsson J; Kumar R; Viswabandya A; Law AD
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1511-1519. PubMed ID: 32422253
[TBL] [Abstract][Full Text] [Related]
22. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Scott BL; Pasquini MC; Logan BR; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick ED; Fernandez HF; Alyea EP; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Le-Rademacher J; Mendizabal AM; Horowitz MM; Deeg HJ; Horwitz ME
J Clin Oncol; 2017 Apr; 35(11):1154-1161. PubMed ID: 28380315
[TBL] [Abstract][Full Text] [Related]
23. Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.
Yanada M; Yamasaki S; Konuma T; Mizuno S; Uchida N; Onai D; Fukuda T; Tanaka M; Ozawa Y; Eto T; Ikegame K; Sawa M; Katayama Y; Kawakita T; Onizuka M; Kanda Y; Ichinohe T; Atsuta Y; Yano S
Int J Hematol; 2023 Mar; 117(3):398-408. PubMed ID: 36335534
[TBL] [Abstract][Full Text] [Related]
24. Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study.
Fein JA; Shouval R; Galimard JE; Labopin M; Socié G; Finke J; Cornelissen JJ; Malladi R; Itälä-Remes M; Chevallier P; Orchard KH; Bunjes D; Aljurf M; Rubio MT; Versluis J; Mohty M; Nagler A
Blood Adv; 2023 May; 7(10):2143-2152. PubMed ID: 36622338
[TBL] [Abstract][Full Text] [Related]
25. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
26. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation.
Ringdén O; Erkers T; Aschan J; Garming-Legert K; Le Blanc K; Hägglund H; Omazic B; Svenberg P; Dahllöf G; Mattsson J; Ljungman P; Remberger M
J Intern Med; 2013 Aug; 274(2):153-62. PubMed ID: 23432209
[TBL] [Abstract][Full Text] [Related]
27. Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation.
Huselton E; Slade M; Trinkaus KM; DiPersio JF; Westervelt P; Romee R
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2047-2055. PubMed ID: 29803753
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
Gilleece MH; Labopin M; Savani BN; Yakoub-Agha I; Socié G; Gedde-Dahl T; Blaise D; Byrne JL; Craddock C; Cornelissen JJ; Arcese W; Forcade E; Crawley C; Polge E; Mohty M; Nagler A
Leukemia; 2020 Jan; 34(1):87-99. PubMed ID: 31363160
[TBL] [Abstract][Full Text] [Related]
29. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
30. Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data.
Yanada M; Fukuda T; Tanaka M; Ota S; Toya T; Mori T; Uchida N; Ozawa Y; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Yano S
Bone Marrow Transplant; 2020 Oct; 55(10):2008-2016. PubMed ID: 32203266
[TBL] [Abstract][Full Text] [Related]
31. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.
Bitan M; He W; Zhang MJ; Abdel-Azim H; Ayas MF; Bielorai B; Carpenter PA; Cairo MS; Diaz MA; Horan JT; Jodele S; Kitko CL; Schultz KR; Kletzel M; Kasow KA; Lehmann LE; Mehta PA; Shah N; Pulsipher MA; Prestidge T; Seber A; Shenoy S; Woolfrey AE; Yu LC; Davies SM
Blood; 2014 Mar; 123(10):1615-20. PubMed ID: 24435046
[TBL] [Abstract][Full Text] [Related]
32. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.
Ringdén O; Labopin M; Ehninger G; Niederwieser D; Olsson R; Basara N; Finke J; Schwerdtfeger R; Eder M; Bunjes D; Gorin NC; Mohty M; Rocha V
J Clin Oncol; 2009 Sep; 27(27):4570-7. PubMed ID: 19652066
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Myeloablative (CyTBI, BuCy) versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Pretransplant Low WT1 Expression.
Park S; Min GJ; Park SS; Yahng SA; Jeon YW; Shin SH; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2018-2026. PubMed ID: 32659434
[TBL] [Abstract][Full Text] [Related]
34. Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.
Passweg JR; Labopin M; Cornelissen J; Volin L; Socié G; Huynh A; Tabrizi R; Wu D; Craddock C; Schaap N; Kuball J; Chevallier P; Cahn JY; Blaise D; Ghavamzadeh A; Bilger K; Ciceri F; Schmid C; Giebel S; Nagler A; Mohty M;
Bone Marrow Transplant; 2015 Aug; 50(8):1063-8. PubMed ID: 26030052
[TBL] [Abstract][Full Text] [Related]
35. Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients.
Topcuoglu P; Arat M; Ozcan M; Arslan O; Ilhan O; Beksac M; Gurman G
Ann Hematol; 2012 Apr; 91(4):577-86. PubMed ID: 21971669
[TBL] [Abstract][Full Text] [Related]
36. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.
Magenau JM; Braun T; Reddy P; Parkin B; Pawarode A; Mineishi S; Choi S; Levine J; Li Y; Yanik G; Kitko C; Churay T; Frame D; Riwes MM; Harris A; Bixby D; Couriel DR; Goldstein SC
Ann Hematol; 2015 Jun; 94(6):1033-41. PubMed ID: 25784222
[TBL] [Abstract][Full Text] [Related]
38. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.
Fasslrinner F; Schetelig J; Burchert A; Kramer M; Trenschel R; Hegenbart U; Stadler M; Schäfer-Eckart K; Bätzel M; Eich H; Stuschke M; Engenhart-Cabillic R; Krause M; Dreger P; Neubauer A; Ehninger G; Beelen D; Berdel WE; Siepmann T; Stelljes M; Bornhäuser M
Lancet Haematol; 2018 Apr; 5(4):e161-e169. PubMed ID: 29550384
[TBL] [Abstract][Full Text] [Related]
39. Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study.
Gatwood KS; Labopin M; Savani BN; Finke J; Socie G; Beelen D; Yakoub-Agha I; Chevallier P; Ganser A; Blaise D; Milpied N; Bruno L; Mailhol A; Mohty M; Nagler A
Bone Marrow Transplant; 2020 Jan; 55(1):224-232. PubMed ID: 31527819
[TBL] [Abstract][Full Text] [Related]
40. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
